What is it about?
ACT has become a promising immunotherapeutic route to cancer treatment. Here we provide a brief history of adoptive T cell therapy, and review the characteristics of T cell therapeutics that are specific to this approach. Since every T cell treatment has its own unique properties in terms of number and type of target antigen, and numbers of epitopes and type of T cell, we review the main strategies for designing ACT: how Ag specificity is determined, how it is standardized, and the need for lymphodepletion to induce epitope spreading. We also consider briefly the next generation of ACT.
Featured Image
Why is it important?
Our findings show that numbers of epitopes and target antigens, lymphodepletion condition, and standardization of T cell production procedure need to be optimized for adoptive cell therapy using antigen-specific T cells.
Perspectives
I would like to researchers interested in adoptive T cell therapy (ACT) that ACT not only need to develop the simple and practical procedure to produce Ag-specific T cells, but also need to consider the standardization of cell production procedure.
Beom K. Choi
National Cancer Center
Read the Original
This page is a summary of: Cancer immunotherapy using tumor antigen-reactive T cells, Immunotherapy, March 2018, Future Medicine,
DOI: 10.2217/imt-2017-0130.
You can read the full text:
Contributors
The following have contributed to this page
